Quinapril‐associated Acute Psychosis in an Older Woman

Tarlow, M J; Sakaris, Antoinette; Wolf‐Klein, Gisele

doi:10.1111/jgs.2000.48.11.1533

Cited by 16 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, study of Wahlbeck et al revealed increased expression of the ACE in response to some stimuli in chronic schizophrenia patients [30]. Finally, clinical observation also found that acute psychosis could be developed as an adverse effect of angiotensin I-converting enzyme inhibition (such as captopril and quinapril) [31,32].…”

Section: Discussionmentioning

confidence: 96%

Genetic polymorphism of the angiotensin converting enzyme and l-dopa-induced adverse effects in Parkinson's disease

Lin

Yueh

Lin

et al. 2007

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Genetic polymorphism of the angiotensin converting enzyme and l-dopa-induced adverse effects in Parkinson's disease

Lin

Yueh

Lin

et al. 2007

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…We cannot draw full conclusions with statistical evidence alone, and these results are not sufficient to justify changes to current prescription guidelines, especially given their known beneficial cardiovascular effects. However, given that visual hallucinations and reversible psychosis have been reported after ACE inhibitor treatment, our findings warrant further research into the functional role of ACE in schizophrenia, as well as greater pharmacovigilance. Access to massive electronic health record databases provide the opportunity to conduct pharmacoepidemiological studies to look at the association between ACE inhibitor use and psychiatric symptoms, hospitalization, and mortality in patients with schizophrenia, or with the incidence of late-onset schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

Association of Antihypertensive Drug Target Genes With Psychiatric Disorders

et al. 2021

View full text Add to dashboard Cite

IMPORTANCEObservational studies have reported associations between antihypertensive medication and psychiatric disorders, although the reported direction of association appears to be dependent on drug class. OBJECTIVE To estimate the potential effect of different antihypertensive drug classes on schizophrenia, bipolar disorder, and major depressive disorder. DESIGN, SETTING, AND PARTICIPANTSThis 2-sample mendelian randomization study assessed the association between a single-nucleotide variant (SNV) and drug target gene expression derived from existing expression quantitative trait loci (eQTL) data in blood (sample 1) and the SNV-disease association from published case-control genome-wide association studies (sample 2). Significant associations were corroborated using published brain eQTL and protein QTL data. Participants included 40 675 patients with schizophrenia and 64 643 controls, 20 352 patients with bipolar disorder and 31 358 controls, and 135 458 patients with major depressive disorder and 344 901 controls. Blood eQTL levels were measured in 31 684 individuals from 37 cohorts (eQTLGen consortium); prefrontal cortex eQTLs were measured from the PsychENCODE resource in 1387 individuals; and protein QTLs were measured in cerebral spinal fluid from 544 individuals and plasma from 818 individuals.

show abstract

“… 56 Psychosis and delirium have been reported rarely with ACE inhibitors. 57 - 59 ACE inhibitors do not appear to have profound cognitive effects, with small trials finding no cognitive dysfunction 60 and perhaps even mild cognitive enhancement 61 among patients taking captopril, but a double-blind trial of an ACE inhibitor, ceranapril, 62 found that this agent did not improve cognition among patients with Alzheimer's disease. ACE inhibitors also demonstrate low rates of fatigue and sedation.…”

Section: Angiotensin-converting Enzyme Inhibitorsmentioning

confidence: 99%

Neuropsychiatric consequences of cardiovascular medications

Huffman

Stern²

2007

Dialogues in Clinical Neuroscience

View full text Add to dashboard Cite

The use of cardiovascular medications can have a variety of neuropsychiatric consequences. Many cardiovascular agents cause higher rates of fatigue and sedation than placebo, and case reports of medication-induced mood syndromes, psychosis, and cognitive disturbances exist for many cardiovascular drugs. Depression has been associated with P3-blockers, methyldopa, and reserpine, but more recent syntheses of the data have suggested that these associations are much weaker than originally believed. Though low cholesterol levels have been associated with depression and suicide, lipid-lowering agents have not been associated with these adverse effects. Finally, cardiovascular medications may have beneficial neuropsychiatric consequences; for example, the use of clonidine in patients with attention deficit-hyperactivity disorder, the use of prazosin for patients with post-traumatic stress disorder; and the use of propranolol for performance anxiety and akathisia.

show abstract

Quinapril‐associated Acute Psychosis in an Older Woman

Cited by 16 publications

References 4 publications

Genetic polymorphism of the angiotensin converting enzyme and l-dopa-induced adverse effects in Parkinson's disease

Genetic polymorphism of the angiotensin converting enzyme and l-dopa-induced adverse effects in Parkinson's disease

Association of Antihypertensive Drug Target Genes With Psychiatric Disorders

Neuropsychiatric consequences of cardiovascular medications

Contact Info

Product

Resources

About